The PI3K family is on industry's ca ncer radarbecauseof the role of these kinases in cell growth, proliferation and differentiation. A decade ago, human genetics studies pointed to an opportunity for PI3K inhibitors in rare immunodeficiency disorders as well. In 2013, researchers reported in5cf'...
兴德通抗肿瘤药物部分项目经验如下: [1] FDA CommitteeShuts Door on Single-Arm Trials for PI3K Inhibitors, Apr 21, 2022,https://www.biospace.com/article/fda-committee-shuts-door-on-single-arm-trials-for-pi3k-inhibitors/ [2] Ribeiro TB, Colunga-Lozano LE, Araujo APV, Bennett CL, Hozo I, D...
(SIMM). By inhibiting PI3K-mediated signaling pathways, cells are blocked in G1 phase, thereby inhibiting tumor cell proliferation. The clinical studies showed that the compound has good safety and preliminary clinical efficacy. At present, no selective PI3Kα inhibitors have been approved for ...
适应证:用于治疗既往已接受至少2种系统性疗法治疗后病情复发的滤泡性淋巴瘤(FL)成人患者。 作用机制:磷脂酰肌醇-3-激酶(PI3K)抑制剂,主要抑制恶性B细胞中表达的PI3K-α和PI3K-δ 剂型与规格:粉针剂,每瓶60 mg。 不良反应:高血糖,腹泻,体力下降,高血压,白细胞减少,...
During April 2022, the a 16 to 0 vote from the FDA’s Oncologic Drugs Advisory Committee voted yes to future approvals of PI3 kinase inhibitors (PI3K) and the FDA granted approval to axicabtagene ciloleucel (Axi-cel;Yescarta) for the treatment of patients with large B-cell lymphoma, a...
会议的起因是,FDA对4款加速获批的PI3Kδ抑制剂的6项临床试验做了回顾性分析[1],发现这些药物竟然因为毒性太强,导致了患者预期寿命的缩短! 即:药物在杀死癌细胞的同时,把患者也给带走了。 由于此前它们都是都凭借单臂试验获批,试验的...
Faslodex is approved as monotherapy or in combination with medicines from various drug classes including CDK4/6, PI3K and AKT inhibitors for the treatment of patients with HR-positive advanced breast cancer and is being evaluated in combination with medicines from other drug classes. ...
然而,Trodelvy的临床益处高度依赖于Trop-2的表达,在低Trop-2表达亚组中很难得出明确的结论。 参考文献: [1] Small-molecule inhibitors, immunecheckpointinhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.Journal of Hematology & Oncology2022....
7、ecularkinaseinhibitorsapprovedbyFDAin2001-2016在获批的31中小分子激酶抑制剂类药物中(图3),绝大多数为酪氨酸激酶抑制剂,还有些属于丝氨酸/苏氨酸激酶抑制剂,只有2014年七月获批的Idelalisib属于脂激酶类抑制剂。根据靶点蛋白及药物属性的不同,分类整理如下:I1. FDA批准的可逆NRTK(非受体型酪氨酸激酶)抑制剂类...
Among these, the pan-AKT inhibitor capivasertib was approved in 2023 in combination with the estrogen receptor degrader fulvestrant for the treatment of ER+ advanced breast cancer after progression on an aromatase inhibitor. However, the clinical development of multiple inhibitors of the PI3K/AKT/...